Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05491226Phase 2Recruiting

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Role: lead

NCT07015853Phase 2Not Yet Recruiting

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Role: lead

NCT03366844Phase 1Active Not Recruiting

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Role: lead

All 3 trials loaded